Re: Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
Tushar M
TM
Ranchod
Victor R
VR
Leverenz
Shravan K
SK
Chintala
Mei
M
Cheng
Michael T
MT
Trese
Frank J
FJ
Giblin
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000009:adverse effects; D000068258:Bevacizumab; D002442:Ceftazidime / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000188:drug therapy / Q000209:etiology*; D015817:Eye Infections / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects*; D000069579:Ranibizumab; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000209:etiology*; D014640:Vancomycin / Q000627:therapeutic use; D014822:Vitreous Body / Q000382:microbiology
D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000068258:Bevacizumab; D014640:Vancomycin; D002442:Ceftazidime; D000069579:Ranibizumab